Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:BBIO NASDAQ:RARE NASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$174.48+0.6%$171.44$111.09▼$183.00$10.61B0.41437,818 shs260,277 shsBBIOBridgeBio Pharma$47.37+0.2%$42.30$21.72▼$48.68$8.98B1.232.19 million shs2.22 million shsRAREUltragenyx Pharmaceutical$28.44+4.1%$33.99$25.81▼$60.37$2.58B0.253.19 million shs2.24 million shsVRNAVerona Pharma PLC American Depositary Share$105.18+0.1%$94.32$18.51▼$105.50$8.95B0.128.02 million shs3.15 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+0.56%+4.19%+0.80%+1.41%+30.70%BBIOBridgeBio Pharma+0.21%+2.31%+10.60%+22.82%+82.54%RAREUltragenyx Pharmaceutical+4.10%+4.02%-27.93%-27.63%-36.83%VRNAVerona Pharma PLC American Depositary Share+0.09%-0.11%+16.76%+44.62%+364.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASNDAscendis Pharma A/S3.0931 of 5 stars4.52.00.00.02.01.70.6BBIOBridgeBio Pharma4.7123 of 5 stars4.53.00.03.93.03.30.6RAREUltragenyx Pharmaceutical4.474 of 5 stars4.51.00.03.83.82.50.6VRNAVerona Pharma PLC American Depositary Share2.1954 of 5 stars2.13.00.00.04.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$223.6728.19% UpsideBBIOBridgeBio Pharma 3.00Buy$61.1829.15% UpsideRAREUltragenyx Pharmaceutical 2.92Moderate Buy$83.08192.11% UpsideVRNAVerona Pharma PLC American Depositary Share 2.15Hold$109.003.63% UpsideCurrent Analyst Ratings BreakdownLatest RARE, ASND, VRNA, and BBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025BBIOBridgeBio PharmaRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$56.007/29/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$245.00 ➝ $254.007/29/2025BBIOBridgeBio PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$95.007/28/2025RAREUltragenyx PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$80.007/21/2025BBIOBridgeBio PharmaTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$66.007/14/2025BBIOBridgeBio PharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $68.007/14/2025BBIOBridgeBio PharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$70.007/14/2025RAREUltragenyx PharmaceuticalWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$35.00 ➝ $34.007/14/2025RAREUltragenyx PharmaceuticalMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$65.00 ➝ $55.007/14/2025VRNAVerona Pharma PLC American Depositary ShareHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$90.00 ➝ $107.007/11/2025ASNDAscendis Pharma A/SCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$213.00 ➝ $243.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$393.54M27.11N/AN/A($1.88) per share-92.81BBIOBridgeBio Pharma$221.90M40.53N/AN/A($7.71) per share-6.14RAREUltragenyx Pharmaceutical$560.23M4.80N/AN/A$2.76 per share10.30VRNAVerona Pharma PLC American Depositary Share$42.28M211.78N/AN/A$2.56 per share41.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$6.28N/A727.00N/A-93.22%N/A-33.29%9/2/2025 (Estimated)BBIOBridgeBio Pharma-$535.76M-$3.53N/AN/AN/A-524.25%N/A-94.43%8/5/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$5.88N/AN/AN/A-93.04%-186.49%-36.81%8/5/2025 (Estimated)VRNAVerona Pharma PLC American Depositary Share-$173.42M-$2.00N/A3,506.00N/AN/A-69.65%-28.00%8/6/2025 (Estimated)Latest RARE, ASND, VRNA, and BBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025VRNAVerona Pharma PLC American Depositary Share$0.39N/AN/AN/A$68.24 millionN/A8/5/2025Q2 2025BBIOBridgeBio Pharma-$0.50N/AN/AN/A$98.46 millionN/A8/5/2025Q2 2025RAREUltragenyx Pharmaceutical-$1.27N/AN/AN/A$161.37 millionN/A5/6/2025Q1 2025RAREUltragenyx Pharmaceutical-$1.54-$1.57-$0.03-$1.57$145.98 million$139.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/AVRNAVerona Pharma PLC American Depositary ShareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.040.71BBIOBridgeBio PharmaN/A4.574.54RAREUltragenyx PharmaceuticalN/A2.402.24VRNAVerona Pharma PLC American Depositary Share1.078.868.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/ABBIOBridgeBio Pharma99.85%RAREUltragenyx Pharmaceutical97.67%VRNAVerona Pharma PLC American Depositary Share85.88%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%BBIOBridgeBio Pharma18.20%RAREUltragenyx Pharmaceutical5.50%VRNAVerona Pharma PLC American Depositary Share4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,01761.15 million36.69 millionOptionableBBIOBridgeBio Pharma400189.88 million155.32 millionOptionableRAREUltragenyx Pharmaceutical1,29494.54 million89.34 millionOptionableVRNAVerona Pharma PLC American Depositary Share3085.13 million81.05 millionOptionableRARE, ASND, VRNA, and BBIO HeadlinesRecent News About These CompaniesBrokerages Set Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Target Price at $109.00August 2 at 2:21 AM | americanbankingnews.comBaader Bank Aktiengesellschaft Acquires Shares of 6,870 Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 31 at 3:56 AM | marketbeat.comGSA Capital Partners LLP Lowers Stock Holdings in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 31 at 3:55 AM | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Stock Holdings Lessened by TD Asset Management IncJuly 31 at 3:46 AM | marketbeat.comVolatility-Proof Your Portfolio With VIPS, GDS, FUTU & VRNA StocksJuly 30 at 11:11 AM | zacks.comFederated Hermes Inc. Sells 557,532 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 30 at 3:20 AM | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Receives Consensus Rating of "Hold" from AnalystsJuly 30 at 2:30 AM | marketbeat.comWedbush Securities Inc. Takes Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 29, 2025 | marketbeat.comMerck’s $10B Verona Deal: A High-Stakes Play in Respiratory CareJuly 29, 2025 | msn.comY Intercept Hong Kong Ltd Takes $721,000 Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 27, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Hits New 52-Week High - Should You Buy?July 26, 2025 | marketbeat.comNew York State Common Retirement Fund Has $976,000 Stock Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 25, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Stake Trimmed by Dorsey Wright & AssociatesJuly 24, 2025 | marketbeat.comBank of New York Mellon Corp Takes Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 24, 2025 | marketbeat.comGW&K Investment Management LLC Sells 38,240 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 23, 2025 | marketbeat.comPathway Capital Management LP Purchases Shares of 98,329 Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 21, 2025 | marketbeat.comVerdence Capital Advisors LLC Makes New Investment in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 21, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Hits New 12-Month High - Here's What HappenedJuly 19, 2025 | marketbeat.comAtle Fund Management AB Acquires New Holdings in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 19, 2025 | marketbeat.comJennison Associates LLC Decreases Stock Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 19, 2025 | marketbeat.comCenterBook Partners LP Acquires Shares of 9,480 Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendThese 3 Rare Earth Stocks Are Surging Alongside MP MaterialsBy Leo Miller | July 19, 2025View These 3 Rare Earth Stocks Are Surging Alongside MP MaterialsMP Materials Stock Booms on New Government PositioningBy Gabriel Osorio-Mazilli | July 14, 2025View MP Materials Stock Booms on New Government PositioningNVIDIA: A Major Indicator Just Flashed Sell, But Should You?By Sam Quirke | July 30, 2025View NVIDIA: A Major Indicator Just Flashed Sell, But Should You?Top 5 Undervalued Dividend Stocks With Strong Payout PotentialBy Ryan Hasson | July 7, 2025View Top 5 Undervalued Dividend Stocks With Strong Payout PotentialRARE, ASND, VRNA, and BBIO Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$174.48 +0.98 (+0.56%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$173.94 -0.53 (-0.31%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.BridgeBio Pharma NASDAQ:BBIO$47.37 +0.10 (+0.21%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$47.00 -0.37 (-0.78%) As of 08/1/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Ultragenyx Pharmaceutical NASDAQ:RARE$28.44 +1.12 (+4.10%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$28.34 -0.11 (-0.37%) As of 08/1/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Verona Pharma PLC American Depositary Share NASDAQ:VRNA$105.18 +0.09 (+0.09%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$105.25 +0.07 (+0.07%) As of 08/1/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
